Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SMBS
Schwab Mortgage-Backed Securities ETF
SMBS
|
+$5.08B |
| 2 |
Schwab Municipal Bond ETF
SCMB
|
+$1.29B |
| 3 |
Schwab US Large-Cap Growth ETF
SCHG
|
+$752M |
| 4 |
Microsoft
MSFT
|
+$699M |
| 5 |
NVIDIA
NVDA
|
+$578M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Mortgage-Backed Securities ETF
VMBS
|
+$4.9B |
| 2 |
Invesco FTSE RAFI US 1000 ETF
PRF
|
+$986M |
| 3 |
iShares National Muni Bond ETF
MUB
|
+$951M |
| 4 |
Invesco FTSE RAFI US 1500 Small-Mid ETF
PRFZ
|
+$794M |
| 5 |
Schwab Fundamental International Small Company Index ETF
FNDC
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.55% |
| 2 | Financials | 11.83% |
| 3 | Healthcare | 9.33% |
| 4 | Consumer Discretionary | 9.25% |
| 5 | Industrials | 8.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GBIO
3426
DELISTED
Generation Bio
GBIO
| $75.8K | ﹤0.01% |
23,686
-11,958
| -34% | -$46.1K |
|
3427
Acrivon Therapeutics
ACRV
$74.5M
| $75.7K | ﹤0.01% |
63,636
-47,684
| -43% | -$65.4K |
|
3428
Lightpath Technologies
LPTH
$789M
| $74.5K | ﹤0.01% |
24,173
| – | – |
|
3429
Genelux
GNLX
$122M
| $71.8K | ﹤0.01% |
25,000
| – | – |
|
3430
Intellicheck
IDN
$76.1M
| $69.9K | ﹤0.01% |
12,962
| – | – |
|
|
VXRT
3431
DELISTED
Vaxart
VXRT
| $69.5K | ﹤0.01% |
153,847
+300
| +0.2% | +$131 |
|
|
AGEN
3432
Agenus
AGEN
$315M
| $68.8K | ﹤0.01% |
15,061
-48,624
| -76% | -$168K |
|
|
GOCO
3433
DELISTED
GoHealth
GOCO
| $66.9K | ﹤0.01% |
12,060
-3,311
| -22% | -$26.2K |
|
3434
InfuSystem Holdings
INFU
$241M
| $66.5K | ﹤0.01% |
10,655
-46,723
| -81% | -$258K |
|
3435
Atossa Therapeutics
ATOS
$23.7M
| $66.4K | ﹤0.01% |
5,333
-22,839
| -81% | -$273K |
|
|
SBC
3436
SBC Medical Group
SBC
$316M
| $66.2K | ﹤0.01% |
+14,267
| New | +$56.4K |
|
3437
Prelude Therapeutics
PRLD
$385M
| $65.4K | ﹤0.01% |
80,845
-33,205
| -29% | -$28.8K |
|
3438
RenovoRx
RNXT
$52.3M
| $65K | ﹤0.01% |
49,232
| – | – |
|
3439
Lineage Cell Therapeutics
LCTX
$286M
| $62K | ﹤0.01% |
68,275
-434,918
| -86% | -$258K |
|
3440
Ondas Inc
ONDS
$5.31B
| $61.4K | ﹤0.01% |
32,000
| – | – |
|
3441
NN Inc
NNBR
$300M
| $59.6K | ﹤0.01% |
28,401
-108,301
| -79% | -$216K |
|
3442
Verde Clean Fuels
VGAS
$27.3M
| $58.9K | ﹤0.01% |
+17,113
| New | +$58.3K |
|
3443
Coya Therapeutics
COYA
$109M
| $57.5K | ﹤0.01% |
10,000
| – | – |
|
3444
Full House Resorts
FLL
$90.5M
| $55.8K | ﹤0.01% |
15,255
-80,111
| -84% | -$268K |
|
3445
ALX Oncology
ALXO
$285M
| $55.4K | ﹤0.01% |
133,433
-77,618
| -37% | -$39.2K |
|
|
CIRC
3446
Circle8 Group
CIRC
$63M
| $54.2K | ﹤0.01% |
+26,705
| New | +$80.4K |
|
|
TWNP
3447
DELISTED
Twin Hospitality Group
TWNP
| $53.2K | ﹤0.01% |
11,772
| – | – |
|
3448
Marchex
MCHX
$79.3M
| $52.5K | ﹤0.01% |
24,313
| – | – |
|
3449
Amplify Energy
AMPY
$172M
| $52.4K | ﹤0.01% |
16,376
-96,966
| -86% | -$288K |
|
3450
DHI Group
DHX
$158M
| $52.3K | ﹤0.01% |
17,605
| – | – |
|
Similar funds
Charles Schwab's Q2 2025 Portfolio in Review
As of Q2 2025, Charles Schwab held 3,631 positions worth $578B, up 8.5% from $533B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Charles Schwab's Q2 2025 filing shows 158 new, 2,252 increased, 1,020 reduced and 137 closed positions. Its largest new stake was Schwab Mortgage-Backed Securities ETF: 202,020,489 shares worth $5.15B. The largest sale was Vanguard Mortgage-Backed Securities ETF, an estimated $4.9B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 21% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q2 2025 buy was Schwab Mortgage-Backed Securities ETF: 202,020,489 shares worth $5.15B.
- Charles Schwab added most to Schwab Municipal Bond ETF in Q2 2025, an estimated $1.29B increase.
- Charles Schwab's biggest Q2 2025 reduction was Vanguard Mortgage-Backed Securities ETF, cutting an estimated $4.9B.
- Charles Schwab fully exited Invesco FTSE RAFI US 1000 ETF in Q2 2025, selling an estimated $986M.
- Charles Schwab's ten largest holdings make up 23% of its $578B portfolio in Q2 2025.
- Charles Schwab opened 158 new positions and closed 137 in Q2 2025.
- Charles Schwab's portfolio value rose 8.5% quarter-over-quarter to $578B.
Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.